History of ADHD

Early descriptions

The earliest medical description of what we now call ADHD dates to 1902, when British paediatrician Sir George Still presented a series of lectures to the Royal College of Physicians. He described children with “an abnormal defect of moral control” who showed significant problems with sustained attention, impulse control, and excessive movement, despite having normal intelligence.

Still’s language reflected his era. “Moral control” did not mean these children were immoral. He was describing what we would now call self-regulation: the ability to inhibit impulses, sustain attention, and behave in ways that aligned with understood expectations. His clinical observations were remarkably detailed and accurate, even if the framework was wrong.

The hyperactivity era

For much of the 20th century, attention difficulties took a back seat to hyperactivity. The condition was known as “hyperkinetic disorder of childhood” or “hyperkinetic reaction of childhood”, and the defining feature was excessive motor activity. Children who were inattentive but not physically hyperactive were largely invisible.

A significant development came in 1937, when American physician Charles Bradley discovered, almost by accident, that amphetamine medication reduced hyperactivity and improved focus in children. This was the first pharmacological treatment and laid the groundwork for stimulant medication, though it took decades for the implications to be fully understood.

From ADD to ADHD

The 1980 DSM-III marked a turning point. The diagnosis was renamed “Attention Deficit Disorder” (ADD), with and without hyperactivity. For the first time, inattention was recognised as the core feature, not just excessive movement. This was significant because it opened the door to recognising people, particularly girls and women, whose difficulties were primarily with focus, organisation, and mental energy rather than physical restlessness.

In 1987, the DSM-III-R consolidated the subtypes into a single diagnosis: Attention-Deficit/Hyperactivity Disorder (ADHD). The 2013 DSM-5 refined the criteria further, adjusting symptom thresholds for adults, recognising that ADHD could co-occur with autism (previously excluded), and formally acknowledging that ADHD persists into adulthood.

The long road to recognising adult ADHD

For decades, ADHD was considered exclusively a childhood condition. The prevailing assumption was that children “grew out of it” by adolescence. This was wrong. Research from the 1990s and 2000s demonstrated conclusively that ADHD persists into adulthood in the majority of cases, though the presentation often changes. Hyperactivity tends to decrease, while inattention, executive dysfunction, and emotional dysregulation remain or become more prominent.

The consequences of this delayed recognition were enormous. Entire generations of adults lived with undiagnosed ADHD, attributing their difficulties to personal failure: laziness, lack of willpower, or not trying hard enough. Many developed secondary mental health conditions, including depression, anxiety, and low self-esteem, as a direct result of years of struggling without understanding why.

Women, girls, and the diagnostic gap

The history of ADHD is also a history of who was seen and who was missed. Research and clinical practice focused overwhelmingly on hyperactive boys for most of the 20th century. Girls with ADHD, who more commonly present with the inattentive type, were systematically overlooked.

The consequences of this gender bias continue today. Women are diagnosed on average 5-10 years later than men, often only after their children are diagnosed and they recognise the traits in themselves. The emotional toll of late diagnosis, including grief, anger, and relief, is a direct legacy of decades of research that looked at the wrong population.

ADHD in the UK

The UK has been slower than some countries to recognise and treat ADHD, particularly in adults. NHS assessment capacity has historically been limited, resulting in waiting lists that can stretch to years in some areas. The introduction of Right to Choose in England has allowed some patients to access assessment through private providers funded by the NHS, but the system remains under significant pressure.

Recent NHS data suggests that approximately 2.5 million people in England have ADHD, though the majority remain undiagnosed. The gap between prevalence and diagnosis reflects the long history of under-recognition.

Further reading on neurobetter

• ADHD - overview
• Getting assessed for ADHD
• Gender differences in ADHD
• The overdiagnosis myth
• Understanding diagnosis

neurobetter services

• Local services directory - find ADHD assessment and support services near you
• Ask a Counsellor - get a confidential response from a registered counsellor